ECOG-ACRIN / EA3231
Trial Overview
Official Title
A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em
Study Purpose
To determine if cabozantinib or the combination of dabrafenib and trametinib works better to prolong the time until the tumor grows or spreads after initial treatment stops working.
Diagnosis
Radioactive Iodine-Refractory Differentiated Thyroid Cancer with BRAF V600E mutation, including papillary thyroid carcinoma and follicular thyroid carcinomaEligibility
Prior I-131 treatment, prior lenvatinib or sorafenib, no prior cabozantinib
Intervention
Daily oral Dabrafenib + Trametinib Vs Cabozantinib
For more information, click the link below:
https://clinicaltrials.gov/study/NCT06475989?term=EA3231&rank=1
Key Participation Requirements
Trial Location(s)
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
EA3231